Less toxic PPAR-γ agonists, such as pioglitazone or rosiglitazone, both FDA approved and commercially available to treatment of diabetes, may prove to be useful chemotherapeutic agents for breast cancer patients. Here, PPARG is linked to breast carcinoma.